
Tekla World Healthcare Fund is a closed-ended balanced mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity and fixed income markets across the globe. It seeks to invest in stocks of companies operating in the healthcare sector. For its fixed income portion, the fund primarily invests in corporate debt securities. Tekla World Healthcare Fund was formed on June 26, 2015 and is domiciled in the United States.
Abrdn World Healthcare Fund trades as THW on NYSE. The company is classified in Financial Services / Asset Management and reports in USD.
The current profile places the business in Asset Management. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.
Latest available fiscal data shows $63.14M of revenue and $55.39M of net income.
Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.
The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.
Abrdn World Healthcare Fund can be compared against peers such as American Century Disciplined Growth Fund, Alger Focus Equity Fund, Blackstone/GSO Strategic Credit Fund, Evercore Equity Fund, Guggenheim Active Allocation Fund, T. Rowe Price Institutional Emerging Markets Equity Fund.
A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.
Current signals to investigate include market capitalization of $501.89M, beta of 0.83, and return on equity of N/A.
This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.
Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.
THW currently shows total debt of N/A and beta of 0.83. Missing data should be treated as a research gap, not as low risk.
Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.
No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.
Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.
No recent SEC-style filings are available for this symbol yet.
Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.
Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.
Company website: https://www.teklacap.com/thw.html
For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.